Zhuoming Guo

Zhuoming Guo

Auto-generated profile, based on publicly available information

Zhuoming Guo

Guangdong Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2024 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
YDYikuan Du
Yikuan Du
ZGZhuoming Guo
Zhuoming Guo
BXBijun Xu
Bijun Xu
YYYujia Yang
Yujia Yang
MHMianda Hu
Mianda Hu
CYChun Yang
Chun Yang
Ibuprofen is commonly used as an over-the-counter (OTC) antipyretic and analgesic. As the frequency of its use increases, there has been a corresponding increase in reports of associated adverse events (AEs). However, these events have not been systematically reported in the literature. Meanwhile, the importance of effective pharmacovigilance in evaluating the benefits and risks of drugs is being recognized. Data were obtained indirectly from FAERS using the OpenVigil 2 database, lexically mapped using software such as MySQL, Microsoft Excel, and the R language, and then subjected to four more rigorous algorithms to detect risk signals associated with ibuprofen AEs. By analyzing data from the past 18 years, 878 ibuprofen-related AEs were identified as primary AEs. Notably, unexpected reproductive system and breast disorders were observed as important system organ classes (SOC) associated with ibuprofen. Among the 651 preferred terms (PTs) that simultaneously satisfied the four arithmetic methods, we propose renal tubular acidosis and lip edema as new signals for AEs of ibuprofen. The study explores the important and valuable potential AEs and ADRs of ibuprofen at the SOC and PT levels, respectively. To provide a reference for decision-making for ibuprofen to promote rational clinical dosing.

19 December 2024 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
YDYikuan Du
Yikuan Du
LZLingzhi Zhang
Lingzhi Zhang
LSLiang Shi
Liang Shi
ZGZhuoming Guo
Zhuoming Guo
ZLZiyi Luo
Ziyi Luo
CYChun Yang
Chun Yang
Based on real data from the FDA Adverse Event Reporting System (FAERS), we explored and evaluated the adverse reactions (ADRs) of sulfasalazine (SSZ) in the first quarter of 2004-2023 to provide a reference basis and early warning for the safe use of SSZ in the clinic. The reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the empirical Bayesian geometric mean (EBGM) were used as measures of SSZ-associated adverse events (AEs) signals, mining for potential positive signals between SSZ and AE. In this study, a total of 5327 case reports related to SSZ in the last 20 years involving 25 system organ classes (SOCs) were collected in FAERS. The AEs of SSZ were mainly focused on Immune system disorders (n = 1621, IC025 = 2.86), Blood and lymphatic system disorders (n = 638, IC025 = 2.4), and others. Notably, the more severe DRESS syndrome was included in Immune system disorders. In addition, we found 41 adverse reactions not mentioned in the specification, including oculomucocutaneous syndrome(n = 12,IC025 = 4.86), wegener's granulomatosis(n = 6, IC025 = 4.05) and reproductive system aspects. Significant new AEs signals were observed in this study and may provide important support for clinical monitoring and risk identification in SSZ.